Bo Jiang, BeiNing Kong, Xiang Fei, XinKun Wan, YuKun Luo
Department of ultrasound, The First Medical Centre, Chinese PLA General Hospital, No. 28 of Fuxing Road, Haidian District, Beijing 100853, China.
Department of Pathology, The First Medical Centre, Chinese PLA General Hospital, No. 28 of Fuxing Road, Haidian District, Beijing 100853, China.
Radiol Case Rep. 2022 Apr 5;17(6):1905-1910. doi: 10.1016/j.radcr.2022.03.010. eCollection 2022 Jun.
Contrast-enhanced ultrasound (CEUS) is one of the important imaging modalities for diagnosis of hepatocellular carcinoma (HCC). Sonovue and Sonazoid are the third-generation of ultrasound contrast agents that have been commercialized and widely used in clinical applications. This study introduces the imaging differences between these two agents in vascular phases for the first time. A 54-year-old man clinical suspected liver cancer. He had chronic hepatitis B for more than 20 years. The result of alpha-fetoprotein was 36.45μg/L (normal< 20μg/L). The imaging pattern of CEUS with Sonovue was "fast-in and fast-out" performance, while the pattern of "fast-out" was absent after portal phase with Sonazoid, even in Kupffer phase. The lesion was diagnosed as lipid-rich HCC by contrast-enhanced MRI. After liver resection, pathology revealed that it was hepatocellular carcinoma contained poor-differentiated steatohepatitis subtype and moderate-differentiated microtrabecular subtype. The imaging difference mainly existed in the part of steatohepatitis subtype. Steatohepatitis subtype HCC can be showed as "fast-in and no wash-out" characteristic in Sonazoid CEUS. Though the mechanism remains not fully clarified, this different enhancing pattern may provide a potential for the supplement of the guidelines and differential of steatohepatitis subtype HCC.
超声造影(CEUS)是诊断肝细胞癌(HCC)的重要影像学方法之一。声诺维(Sonovue)和超声造影剂(Sonazoid)是已商业化并广泛应用于临床的第三代超声造影剂。本研究首次介绍了这两种造影剂在血管期的成像差异。一名54岁男性临床怀疑患有肝癌。他患有慢性乙型肝炎20多年。甲胎蛋白结果为36.45μg/L(正常<20μg/L)。声诺维CEUS的成像模式为“快进快出”表现,而使用超声造影剂(Sonazoid)时,即使在库普弗细胞期,门静脉期后也不存在“快出”模式。通过对比增强磁共振成像(MRI)将病变诊断为富含脂质的HCC。肝切除术后,病理显示为肝细胞癌,包含低分化脂肪性肝炎亚型和中分化微小梁亚型。成像差异主要存在于脂肪性肝炎亚型部分。脂肪性肝炎亚型HCC在超声造影剂(Sonazoid)CEUS中可表现为“快进无廓清”特征。尽管其机制仍未完全阐明,但这种不同的增强模式可能为补充指南及鉴别脂肪性肝炎亚型HCC提供潜力。